{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T15:10:11Z","timestamp":1785769811629,"version":"3.56.0"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"15","license":[{"start":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T00:00:00Z","timestamp":1775779200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Nantong Municipal Science and Technology plan Project","award":["MSZ20172"],"award-info":[{"award-number":["MSZ20172"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,4,10]]},"abstract":"<jats:p>\n                    This study aimed to explore the efficacy of lamivudine\u2005+\u2005zidovudine plus nevirapine and efavirenz in the treatment hf human immunodeficiency virus (HIV)\/acquired immune deficiency syndrome (AIDS). A total of 100 patients with HIV\/AIDS admitted to our hospital from June 2021 to September 2024 were selected and randomly assigned into nevirapine and efavirenz groups (n\u2005=\u200550 per group). The nevirapine group was treated with lamidudine plus zidovudine combined with nevirapine, and the efavirenz group was treated with lamidudine plus zidovudine plus efavirenz. The primary outcomes measured were the changes of lymphocyte count and adverse effects after 3 months of treatment. There was no statistical difference in baseline information between the 2 groups. After treatment, CD3\u2005+\u2005and CD4\u2005+\u2005levels were higher in the nevirapine group than in the efavirenz group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05, 95% CI: 45.2\u201398.7 for CD3\u2005+\u2005and 32.8\u201376.4 for CD4+), and CD8\u2005+\u2005levels were lower in the nevirapine group than in the efavirenz group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05); the overall incidence of adverse effects in the nevavirapine group was significantly lower than that in the efavirenz group (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    \u2005&lt;.05). In HIV\/AIDS patients, treatment with lamivudine\u2005+\u2005zidovudine combined with nevirapine resulted in significantly improved CD4\u2005+\u2005T cell counts, enhanced immune function, and fewer adverse reactions compared to treatment with lamivudine\u2005+\u2005zidovudine plus efavirenz, suggesting superior clinical value of the nevirapine-containing regimen.\n                  <\/jats:p>","DOI":"10.1097\/md.0000000000048049","type":"journal-article","created":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T17:01:24Z","timestamp":1775840484000},"page":"e48049","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparative evaluation of human T lymphocytes in HIV patients treated with lamivudine + zidovudine combined with nevirapine versus efavirenz"],"prefix":"10.1097","volume":"105","author":[{"given":"Xiaohong","family":"Zhu","sequence":"first","affiliation":[{"name":"Nantong University Affiliated Nantong Third Hospital, Nantong City, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5436-510X","authenticated-orcid":false,"given":"Meiyin","family":"Zou","sequence":"additional","affiliation":[{"name":"Nantong University Affiliated Nantong Third Hospital, Nantong City, Jiangsu Province, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20260410","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1016\/j.bmcl.2012.02.037","article-title":"Short cyclic peptides derived from the C-terminal sequence of \u03b11-antitrypsin exhibit significant anti-HIV-1 activity.","volume":"22","author":"Jia","year":"2012","journal-title":"Bioorganic Med Chem Lett"},{"key":"R2-20260410","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.sbi.2015.04.004","article-title":"HIV suppression by host restriction factors and viral immune evasion.","volume":"31","author":"Jia","year":"2015","journal-title":"Curr Opin Struct Biol"},{"key":"R3-20260410","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/s41467-023-36772-x","article-title":"Phenotypic characterization of single CD4+ T cells harboring genetically intact and inducible HIV genomes.","volume":"14","author":"Dufour","year":"2023","journal-title":"Nat Commun"},{"key":"R4-20260410","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s15010-024-02402-x","article-title":"Epidemiological changes and outcomes of people living with HIV admitted to the intensive care unit: a 14-year retrospective study.","volume":"53","author":"Mart\u00ednez","year":"2025","journal-title":"Infection"},{"key":"R5-20260410","doi-asserted-by":"crossref","first-page":"e831","DOI":"10.1016\/S2352-3018(19)30196-1","article-title":"GBD 2017 HIV collaborators. Global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2017, and forecasts to 2030, for 195 countries and territories: a systematic analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017.","volume":"6","year":"2019","journal-title":"Lancet HIV"},{"key":"R6-20260410","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1056\/NEJM199808063390612","article-title":"Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection.","volume":"339","author":"Michaels","year":"1998","journal-title":"N Engl J Med"},{"key":"R7-20260410","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1097\/COH.0000000000000488","article-title":"Post-treatment and spontaneous HIV control.","volume":"13","author":"Martin","year":"2018","journal-title":"Curr Opinion HIV AIDS"},{"key":"R8-20260410","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.idc.2014.06.001","article-title":"Antiretroviral therapy: current drugs.","volume":"28","author":"Pau","year":"2014","journal-title":"Infect Dis Clin North Am"},{"key":"R9-20260410","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1159\/000334167","article-title":"HIV and drug resistance - interpretation and therapeutic progress.","volume":"55","author":"G\u00fcrtler","year":"2012","journal-title":"Intervirology"},{"key":"R10-20260410","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/00128072-200002050-00005","article-title":"Nevirapine: a review of its use in the prevention and treatment of paediatric HIV infection.","volume":"2","author":"Bardsley-Elliot","year":"2000","journal-title":"Paediatr Drugs"},{"key":"R11-20260410","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.2165\/00003495-199856060-00014","article-title":"Efavirenz.","volume":"56","author":"Adkins","year":"1998","journal-title":"Drugs"},{"key":"R12-20260410","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1128\/AAC.00976-10","article-title":"Combinatorial approaches to the prevention and treatment of HIV-1 infection.","volume":"55","author":"Pirrone","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"R13-20260410","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1111\/hiv.12310","article-title":"Immune activation in the course of HIV-1 infection: causes, phenotypes and persistence under therapy.","volume":"17","author":"Younas","year":"2016","journal-title":"HIV Med"},{"key":"R14-20260410","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1016\/j.idc.2019.05.004","article-title":"Management of virologic failure and HIV drug resistance.","volume":"33","author":"McCluskey","year":"2019","journal-title":"Infect Dis Clin North Am"},{"key":"R15-20260410","first-page":"35","article-title":"Influence of immune activation and inflammatory response on cardiovascular risk associated with the human immunodeficiency virus.","volume":"11","author":"Beltr\u00e1n","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"R16-20260410","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.3389\/fimmu.2019.02968","article-title":"Update on Fc-mediated antibody functions against HIV-1 beyond neutralization.","volume":"10","author":"Su","year":"2019","journal-title":"Front Immunol"},{"key":"R17-20260410","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1097\/QAD.0000000000000125","article-title":"CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission.","volume":"28","author":"Li","year":"2014","journal-title":"AIDS"},{"key":"R18-20260410","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/JLB.4MR1019-189R","article-title":"Incomplete immune reconstitution in HIV\/AIDS patients on antiretroviral therapy: challenges of immunological non-responders.","volume":"107","author":"Yang","year":"2020","journal-title":"J Leukoc Biol"},{"key":"R19-20260410","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/QAI.0000000000001660","article-title":"Twenty-five years of lamivudine: current and future use for the treatment of HIV-1 infection.","volume":"78","author":"Quercia","year":"2018","journal-title":"J Acquired Immune Deficiency Syndromes (1999)"},{"key":"R20-20260410","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.apsb.2021.11.009","article-title":"Approved HIV reverse transcriptase inhibitors in the past decade.","volume":"12","author":"Li","year":"2022","journal-title":"Acta Pharmaceutica SINICA. B"},{"key":"R21-20260410","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1002\/med.2610120103","article-title":"Inhibition of HIV-1 reverse transcriptase and virus replication by a non-nucleoside dipyridodiazepinone BI-RG-587 (Nevirapine).","volume":"12","author":"Skoog","year":"1992","journal-title":"Med Res Rev"},{"key":"R22-20260410","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/biom13010088","article-title":"Efavirenz: history, development and future.","volume":"13","author":"Costa","year":"2022","journal-title":"Biomolecules"},{"key":"R23-20260410","doi-asserted-by":"crossref","first-page":"e14372","DOI":"10.1111\/cbdd.14372","article-title":"Current insights and molecular docking studies of HIV-1 reverse transcriptase inhibitors.","volume":"103","author":"Singh","year":"2024","journal-title":"Chem Biol Drug Design"},{"key":"R24-20260410","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1080\/17425255.2019.1673367","article-title":"Current and emerging non-nucleoside reverse transcriptase inhibitors (NNRTIs) for HIV-1 treatment.","volume":"15","author":"Wang","year":"2019","journal-title":"Expert Opinion Drug Metabol Toxicol"},{"key":"R25-20260410","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.coviro.2021.09.009","article-title":"Drug resistance mutations in HIV: new bioinformatics approaches and challenges.","volume":"51","author":"Blassel","year":"2021","journal-title":"Current Opinion Virol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048049","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T14:21:51Z","timestamp":1785766911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1097\/MD.0000000000048049"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,10]]},"references-count":25,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000048049","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,10]]},"assertion":[{"value":"2024-12-21","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-02-24","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}